Serum Anticholinergic Activity : A Possible Peripheral Marker of the Anticholinergic Burden in the Central Nervous System in Alzheimer’s Disease

Serum Anticholinergic Activity : A Possible Peripheral Marker of the Anticholinergic Burden in the Central Nervous System in Alzheimer’s Disease

We review the utility of serum anticholinergic activity (SAA) as a peripheral marker of anticholinergic activity (AA) in the central nervous system (CAA). We hypothesize that the compensatory mechanisms of the cholinergic system do not contribute to SAA if their system is intact and that if central...

Full description

Saved in:
Bibliographic Details
Published in:Disease markers Vol. 2014; no. 2014; pp. 1 - 7
Main Authors: Tani, Masayuki, Konishi, Kimiko, Hori, Koji, Tomioka, Hiroi, Akita, Ryo, Kitajima, Yuka, Aoki, Mari, Yokoyama, Sachiko, Azuma, Kazunari, Ikuse, Daisuke, Akashi, Norihisa, Hosoi, Misa, Jinbo, Koichi, Hachisu, Mitsugu
Format: Journal Article
Language:English
Published: Cairo, Egypt Hindawi Puplishing Corporation 01-01-2014
Hindawi Publishing Corporation
John Wiley & Sons, Inc
Subjects:
Acetylcholine - blood
Alzheimer Disease - blood
Alzheimer's disease
Biological markers
Biomarkers - blood
Central Nervous System - metabolism
Diagnosis
Dosage and administration
Drug interactions
Drug therapy
Humans
Identification and classification
Medical research
Medicine, Experimental
Parasympatholytic agents
Review
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We review the utility of serum anticholinergic activity (SAA) as a peripheral marker of anticholinergic activity (AA) in the central nervous system (CAA). We hypothesize that the compensatory mechanisms of the cholinergic system do not contribute to SAA if their system is intact and that if central cholinergic system deteriorates alone in conditions such as Alzheimer’s disease or Lewy body dementia, CAA and SAA are caused by way of hyperactivity of inflammatory system and SAA is a marker of the anticholinergic burden in CNS. Taking into account the diurnal variations in the plasma levels of corticosteroids, which are thought to affect SAA, it should be measured at noon or just afterward.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Academic Editor: Esperanza Ortega
ISSN:0278-0240
1875-8630
DOI:10.1155/2014/459013